Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2000-Year of the Biotechs! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (450)	3/6/2000 1:04:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 1142

IMO AQLA is a "diamond in the rough" and they have a very impressive list of alliance partners. This news released today..."Aquila Biopharmaceuticals' QS-21 Is Key Component in Several New Vaccines In the Clinic - SmithKline Beecham Malaria Vaccine Scheduled for African Pediatric Trial - FRAMINGHAM, Mass., March 6 /PRNewswire/ -- A promising malaria vaccine under development by Aquila Biopharmaceuticals, Inc.'s (Nasdaq: AQLA - news) partner SmithKline Beecham (SB) is scheduled for testing in pediatric trials in The Gambia, Africa as early as this Fall, Aquila said. The malaria vaccine contains Aquila's QS-21 immune enhancement product as a key component. SB recently announced the planned trial as part of their commitment to the President's Millennium Vaccine Initiative. Aquila supplied the QS-21 adjuvant to SB Biologicals, the vaccine developer, under an agreement between the two companies to test QS-21 in a wide range of vaccines. ``SmithKline Beecham's support of the President's Millennium Vaccine Initiative and the highlighting of the malaria vaccine trial underscore their commitment to developing innovative vaccines. QS-21 is a key component in several vaccines under development for malaria, as well as products for other diseases including cancer and HIV. Aquila is also developing a tuberculosis product using its novel CD1 technology,' said Alison Taunton-Rigby, President and CEO of Aquila. Dr. Taunton-Rigby added that Aquila has additional vaccines under development, including products for melanoma (GMK) with Bristol-Myers Squibb/Progenics Pharmaceuticals, HIV with Aventis Pasteur and VaxGen, Alzheimer's Disease with Elan Corporation, as well as therapeutic vaccines for Hepatitis B and Human Papillomavirus with SB. SB's candidate prophylactic malaria vaccine has shown promising results in clinical trials conducted in collaboration with the Walter Reed Army Institute and the London-based Medical Research Council (MRC) conducted in The Gambia. QS-21, Aquila's lead Stimulon© adjuvant, enhances the body's immune response. The product has been evaluated in a large number of Phase I, Phase II and Phase III clinical trials (about 50 different human clinical trials have been completed involving over 2000 subjects to date). The Stimulon© family of adjuvants has been shown to enhance the quality and quantity of the immune response to a variety of antigens, both in pre-clinical and human clinical trials. Combining disease-specific antigens with Stimulon© adjuvants is designed to enable the development of a new generation of products that specifically and potently enhance disease-targeted immune responses. Aquila Biopharmaceuticals, Inc. is a life sciences company developing and commercializing a range of proprietary products that enhance the immune response in animals and humans. The Company's products are intended for use in treating, controlling and preventing infectious disease, cancers and autoimmune disorders. Aquila's products include: Leucogen© for protection against feline leukemia virus (approved for U.S. and European use in 1991); Quilvax-M(TM), an aid in the control of bovine mastitis; Quilimmune-P(TM) for preventing pneumonia in the elderly; and Quilimmune-M(TM), a human healthcare product for preventing malaria. The Company also licenses its immune enhancement technologies, and current partners include SmithKline Beecham, Elan Corporation, plc, Aventis Pasteur, Wyeth Lederle, VaxGen, Bristol-Myers Squibb (Progenics Pharmaceuticals) and Virbac S.A. Also, a nice release today from NABI. What an array of "potential" drugs/vaccines this company is working on....and they are showing a profit!